View Exam | PowerPak

1. In 2021, approximately how many Americans aged 65 years and older lived with Alzheimer's disease (AD) in the United States alone?

A. 2 million B. 4 million C. 5 million D. 6 million E. Unsure

2. Which of the following are characteristic of the early preclinical stages of AD?

A. Asymptomatic plus no evidence of amyloid-beta (Aβ) deposition B. Asymptomatic plus evidence of Aβ deposition C. Noticeable cognitive decline plus no evidence of Aβ deposition D. Noticeable cognitive decline plus evidence of Aβ deposition E. Unsure

3. Which of the following should be present for a clinical diagnosis of mild cognitive impairment (MCI) due to AD?

A. Concerned about declining cognition B. Declining cognition should be less than expected for the patient's age C. Moderate functional impairment D. Symptoms interfere with daily activities E. Unsure

4. According to the amyloid cascade hypothesis, what is the earliest sign of AD-related neuropathological changes?

A. Aggregated Aβ deposition B. Aggregated tau C. Neurodegeneration D. Neurotoxicity E. Unsure

5. Which of the following is an Aβ monoclonal antibody in late-stage clinical development that has shown promising results on reducing Aβ plaques?

A. Gosuranemab B. Lecanemab C. Semorinemab D. Tilavonemab E. Unsure

6. Please refer to the following case scenario when answering Questions 6-10:
LT is a 72-year-old female with a history of MCI due to AD that has been stable for the past year on donepezil, and her last Mini-Mental State Examination (MMSE) score was 26. Her other medications include atorvastatin, metformin, and hydrochlorothiazide.

LT wants to know if she would be a good candidate for a disease-modifying therapy she heard about on the news called aducanumab. Which of the following is an accurate consideration when addressing her question?

A. Aducanumab was studied in patients with either MCI due to AD or mild AD B. Aducanumab trials required patients to have a baseline MMSE score of less than 23 C. The mean age of study participants in ENGAGE and EMERGE (phase 3 studies) was 87 years D. During aducanumab's phase 3 studies, patients were excluded if they were taking a cholinesterase inhibitor or memantine E. Unsure

7. LT wants to know what lifestyle modifications she can make to prevent or delay her MCI from progressing to dementia. Which of the following are modifiable risk strategies you can discuss with LT?

A. Genetic testing B. Higher level of education C. Controlling her diabetes D. Avoiding social interaction E. Unsure

8. LT's daughter calls the pharmacy and wants to know, which biomarkers measure aggregate Aβ?

A. Anatomic magnetic resonance imaging (MRI) B. Cerebrospinal fluid phosphorylated tau (CSF p-tau) C. Tau positron emission tomography (PET) D. CSF Aβ42 E. Unsure

9. LT and her daughter are concerned about the risk of amyloid-related imaging abnormalities (ARIA) with aducanumab. How many of the patients enrolled in the phase 3 clinical trials (ENGAGE and EMERGE) who received the high dose experienced ARIA?

A. 15% B. 25% C. 40% D. 50% E. Unsure

10. LT asks if you offer cognitive memory screening tests at the pharmacy. After talking with your supervisor, you both agree this is a good service to add to your chronic disease screening events. Which of the following screening questionnaires would be the best suited for your community pharmacy-based program?

A. Mini-Cog B. Mini-Mental State Examination (MMSE) C. Montreal Cognitive Assessment (MoCA) D. Clinical Dementia Rating–Sum of Boxes (CDR-SB) E. Unsure

Evaluation Questions

11. How confident are you in your treatment choices for LT?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In 2021, approximately how many Americans aged 65 years and older lived with Alzheimer's disease (AD) in the United States alone?

2. Which of the following are characteristic of the early preclinical stages of AD?

3. Which of the following should be present for a clinical diagnosis of mild cognitive impairment (MCI) due to AD?

4. According to the amyloid cascade hypothesis, what is the earliest sign of AD-related neuropathological changes?

5. Which of the following is an Aβ monoclonal antibody in late-stage clinical development that has shown promising results on reducing Aβ plaques?

7. LT wants to know what lifestyle modifications she can make to prevent or delay her MCI from progressing to dementia. Which of the following are modifiable risk strategies you can discuss with LT?

8. LT's daughter calls the pharmacy and wants to know, which biomarkers measure aggregate Aβ?

9. LT and her daughter are concerned about the risk of amyloid-related imaging abnormalities (ARIA) with aducanumab. How many of the patients enrolled in the phase 3 clinical trials (ENGAGE and EMERGE) who received the high dose experienced ARIA?

Evaluation Questions

11. How confident are you in your treatment choices for LT?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In 2021, approximately how many Americans aged 65 years and older lived with Alzheimer's disease (AD) in the United States alone?

2. Which of the following are characteristic of the early preclinical stages of AD?

3. Which of the following should be present for a clinical diagnosis of mild cognitive impairment (MCI) due to AD?

4. According to the amyloid cascade hypothesis, what is the earliest sign of AD-related neuropathological changes?

5. Which of the following is an Aβ monoclonal antibody in late-stage clinical development that has shown promising results on reducing Aβ plaques?

7. LT wants to know what lifestyle modifications she can make to prevent or delay her MCI from progressing to dementia. Which of the following are modifiable risk strategies you can discuss with LT?

8. LT's daughter calls the pharmacy and wants to know, which biomarkers measure aggregate Aβ?

9. LT and her daughter are concerned about the risk of amyloid-related imaging abnormalities (ARIA) with aducanumab. How many of the patients enrolled in the phase 3 clinical trials (ENGAGE and EMERGE) who received the high dose experienced ARIA?

Evaluation Questions

11. How confident are you in your treatment choices for LT?

« Return to Activity

Customers who Purchased
this Activity also Purchased